NRIX — Nurix Therapeutics Share News
0.000.00%
Last trade - 00:00- $2.73bn
- $1.68bn
- $83.98m
Brief: Nurix Extends Gilead Collaboration For Oncology Program
Commercialize Potential Best-In-Class Btk Degrader Bexobrutideg Across Malignant Hematology, Immunology And Neurology
Nurix Therapeutics Q2 revenue falls sharply, net loss widens; strikes up to $2.3 bln collab with Roche
U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis
Brief: Nurix Therapeutics To Report Updated Phase 1A/B Results For Btk Degrader Bexobrutideg, Highlighting Durable Responses In Relapsed/Refractory Cll/Sll And Promising Activity In Earlier Lines Of Therapy
U.S. STOCKS ON THE MOVE -Blackstone, Intel, Ciena
U.S. STOCKS ON THE MOVE -Tango Therapeutics, Intel, Ciena
Roche enters cancer drug deal worth up to $2.3 billion with Nurix Therapeutics (updated)
U.S. STOCKS ON THE MOVE-Campbell's, VinFast, Corning
U.S. STOCKS ON THE MOVE-Marvell, Nvidia, Broadcom
Nurix Therapeutics jumps on $2 billion cancer drug agreement with Roche
Roche enters $2 billion cancer drug agreement with Nurix Therapeutics
Press Digest: Wall Street Journal - June 8
Brief: Nurix Therapeutics Announces Bexobrutideg Oral Presentation
U.S. RESEARCH ROUNDUP-Comstock Resources, Trustmark, Viasat
Nurix Therapeutics Q1 loss widens on higher costs
Brief: Nurix Therapeutics Announces Presentations Showcasing Depth Of Research Pipeline And Scientific Leadership At The American Association For Cancer Research (AACR) Annual Meeting
Australia's Nurix Therapeutics Q4 net loss widens
U.S. STOCKS ON THE MOVE-Five Below, Boeing, Instacart